We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Resverlogix Presents at Biotech Showcase During JP Morgan Week

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "Resverlogix Presents at Biotech Showcase During JP Morgan Week"

Listen with
Register for FREE to listen to this article
Thank you. Listen to this article using the player above.
Read time:

Resverlogix Corp. has announced that Donald McCaffrey, president and chief executive officer presented at the 7th Annual Biotech Showcase Conference 2015 during JP Morgan week. The presentation can be accessed via the following link: http://edge.media-server.com/m/p/5wz2z9gn.

Mr. McCaffrey was excited to share developments of the Company's proposed new phase 3 clinical trial BETONMACE. "This trial represents an unprecedented opportunity to reduce major adverse coronary events "MACE" in patients with diabetes. RVX-208 is the only selective BET-Bromodomain inhibitor in clinical trials to reduce the risk of death by cardiac events in patients with CVD and diabetes."